elotuzumab-话题@MedSci - 梅斯（MedSci）

#elotuzumab#

8篇内容 | 1168人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2189625, encodeId=f8d62189625d4, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=e1fa6690af' target=_blank style='color:#2F92EE;'>#elotuzumab#</a>, objectTitle=【柳叶刀-血液病学】Elotuzumab治疗NDMM再遭失败：3期GMMG-HD6研究结果, objectType=article, longId=814830, objectId=2766814830c8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-doctor-hand-with-pen-BWV9L2K.jpg, objectUrl=/article/show_article.do?id=2766814830c8, replyNumber=0, likeNumber=78, createdTime=2024-02-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2766814830c8, moduleTitle=【柳叶刀-血液病学】Elotuzumab治疗NDMM再遭失败：3期GMMG-HD6研究结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2766814830c8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1718258, encodeId=d1cd1e1825875, content=<a href='/topic/show?id=e1fa6690af' target=_blank style='color:#2F92EE;'>#elotuzumab#</a>, objectTitle=JAMA Oncol：Elotuzumab联合每周KRd治疗新诊断的多发性骨髓瘤, objectType=article, longId=734229, objectId=6890e34229fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6890e34229fe, replyNumber=0, likeNumber=123, createdTime=2023-06-18, rootId=0, userName=yyj073, userId=2be932523551, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6890e34229fe, moduleTitle=JAMA Oncol：Elotuzumab联合每周KRd治疗新诊断的多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6890e34229fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718257, encodeId=c35a1e1825742, content=<a href='/topic/show?id=e1fa6690af' target=_blank style='color:#2F92EE;'>#elotuzumab#</a>, objectTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, objectType=article, longId=206006, objectId=dea22060068e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dea22060068e, replyNumber=0, likeNumber=64, createdTime=2021-08-04, rootId=0, userName=yyj073, userId=2be932523551, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dea22060068e, moduleTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dea22060068e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718256, encodeId=01e81e18256f6, content=<a href='/topic/show?id=e1fa6690af' target=_blank style='color:#2F92EE;'>#elotuzumab#</a>, objectTitle=欧盟批准elotuzumab联合泊马度胺和低剂量地塞米松（EPd）治疗复发和难治性多发性骨髓瘤, objectType=article, longId=178293, objectId=b7be1e8293c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7be1e8293c3, replyNumber=0, likeNumber=76, createdTime=2020-01-18, rootId=0, userName=yyj073, userId=2be932523551, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7be1e8293c3, moduleTitle=欧盟批准elotuzumab联合泊马度胺和低剂量地塞米松（EPd）治疗复发和难治性多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b7be1e8293c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718255, encodeId=bdce1e18255d1, content=<a href='/topic/show?id=e1fa6690af' target=_blank style='color:#2F92EE;'>#elotuzumab#</a>, objectTitle=Elotuzumab促进独特的SLAMF7-SLAMF7相互作用，增强骨髓瘤的细胞毒性, objectType=article, longId=178055, objectId=dbc11e80558d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbc11e80558d, replyNumber=0, likeNumber=83, createdTime=2019-11-14, rootId=0, userName=yyj073, userId=2be932523551, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbc11e80558d, moduleTitle=Elotuzumab促进独特的SLAMF7-SLAMF7相互作用，增强骨髓瘤的细胞毒性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dbc11e80558d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718253, encodeId=d32d1e1825366, content=<a href='/topic/show?id=e1fa6690af' target=_blank style='color:#2F92EE;'>#elotuzumab#</a>, objectTitle=Lancet Haematology：复发性多发性骨髓瘤：Elotuzumab有良好的安全性和疗效性, objectType=article, longId=58894, objectId=8c0b5889437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c0b5889437, replyNumber=0, likeNumber=94, createdTime=2016-01-30, rootId=0, userName=yyj073, userId=2be932523551, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c0b5889437, moduleTitle=Lancet Haematology：复发性多发性骨髓瘤：Elotuzumab有良好的安全性和疗效性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8c0b5889437)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718252, encodeId=8f8a1e1825277, content=<a href='/topic/show?id=e1fa6690af' target=_blank style='color:#2F92EE;'>#elotuzumab#</a>, objectTitle=复发性/难治性多发性骨髓瘤患者的福音：Elotuzumab疗法, objectType=article, longId=55116, objectId=9ff455116d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ff455116d1, replyNumber=0, likeNumber=67, createdTime=2016-02-01, rootId=0, userName=yyj073, userId=2be932523551, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ff455116d1, moduleTitle=复发性/难治性多发性骨髓瘤患者的福音：Elotuzumab疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9ff455116d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718254, encodeId=79781e18254c1, content=<a href='/topic/show?id=e1fa6690af' target=_blank style='color:#2F92EE;'>#elotuzumab#</a>, objectTitle=ASH 2015：免疫调节单抗elotuzumab持续改善多发性骨髓瘤无进展生存期, objectType=article, longId=60415, objectId=514f6041501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=514f6041501, replyNumber=0, likeNumber=58, createdTime=2016-09-13, rootId=0, userName=yyj073, userId=2be932523551, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=514f6041501, moduleTitle=ASH 2015：免疫调节单抗elotuzumab持续改善多发性骨髓瘤无进展生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=514f6041501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718251, encodeId=8b101e1825174, content=<a href='/topic/show?id=e1fa6690af' target=_blank style='color:#2F92EE;'>#elotuzumab#</a>, objectTitle=FDA授予elotuzumab单抗作为多发性骨髓瘤突破性疗法认定, objectType=article, longId=35044, objectId=ac55350442f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac55350442f, replyNumber=0, likeNumber=79, createdTime=2014-10-13, rootId=0, userName=yyj073, userId=2be932523551, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac55350442f, moduleTitle=FDA授予elotuzumab单抗作为多发性骨髓瘤突破性疗法认定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ac55350442f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

elotuzumab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #elotuzumab#

【柳叶刀-血液病学】Elotuzumab治疗NDMM再遭失败：3期GMMG-HD6研究结果

2024-02-27发表于上海

yyj073 (审核中...)

前往app查看评论内容

#elotuzumab#

JAMA Oncol：Elotuzumab联合每周KRd治疗新诊断的多发性骨髓瘤

2023-06-18

yyj073 (审核中...)

前往app查看评论内容

#elotuzumab#

Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤

2021-08-04

yyj073 (审核中...)

前往app查看评论内容

#elotuzumab#

欧盟批准elotuzumab联合泊马度胺和低剂量地塞米松（EPd）治疗复发和难治性多发性骨髓瘤

2020-01-18

yyj073 (审核中...)

前往app查看评论内容

#elotuzumab#

Elotuzumab促进独特的SLAMF7-SLAMF7相互作用，增强骨髓瘤的细胞毒性

2019-11-14

yyj073 (审核中...)

前往app查看评论内容

#elotuzumab#

Lancet Haematology：复发性多发性骨髓瘤：Elotuzumab有良好的安全性和疗效性

2016-01-30

yyj073 (审核中...)

前往app查看评论内容

#elotuzumab#

复发性/难治性多发性骨髓瘤患者的福音：Elotuzumab疗法

2016-02-01

yyj073 (审核中...)

前往app查看评论内容

#elotuzumab#

ASH 2015：免疫调节单抗elotuzumab持续改善多发性骨髓瘤无进展生存期

2016-09-13

yyj073 (审核中...)

前往app查看评论内容

#elotuzumab#

FDA授予elotuzumab单抗作为多发性骨髓瘤突破性疗法认定

2014-10-13

科室
- - 订阅+
  - 更多科室
工具
服务